SPARC enters into licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target Read more
GSK and Oxford University announce Oxford-GSK Institute of Molecular and Computational Medicine Read more
Amgen announces positive top-line results from Otezla phase-III Discreet study in moderate-to-severe genital psoriasis Read more